ZAO VERTEX

What ZAO VERTEX does

ZAO VERTEX is a Russian pharmaceutical manufacturer founded in 1999 and headquartered in Saint Petersburg, producing prescription drugs, over-the-counter medicines, cosmetics, and biologically active supplements. The company operates an Innovation and Production Complex spanning 56,500 m² and holds 18 patents, including 6 original combined drugs reported to have no analogues on the Russian market. Its portfolio comprises 430+ product positions, with notable recent launches including the prescription drug Frizanta in December 2024.

Vertex distributes through 83,000+ pharmacies across 50+ Russian cities, 50+ e-commerce platforms, and exports to 10 countries including a new entry into Laos. The company is positioned among the top-3 Russian pharmaceutical manufacturers and ranked 32nd in the Expert Northwest top-300 real-sector ranking in 2025 (up 10 positions year-over-year). It holds Russian GMP, EAEU GMP (acquired 2024), ISO 9001, ISO 22000, and ISO 45001 certifications, and received the Russian Government Quality Award in 2017. Research partnerships with the Almazov National Medical Research Centre (initiated 2016, renewed 2019) support pipeline development in original formulations.

The business model centers on branded generic and proprietary pharmaceutical manufacturing sold through pharmacy retail, e-commerce, public healthcare procurement, and export channels. A cross-border transaction with Dr. Reddy's Laboratories in August 2026 transferred rights to Vertex's gynecological drug portfolio, signaling external validation of the company's IP by a global generic manufacturer. Capacity is structured to support production volume growth of up to 30% annually across the existing SKU base.

Name

ZAO VERTEX

Legal name

Акционерное общество «ВЕРТЕКС» (JSC VERTEX)

Website

https://vertex.spb.ru

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

11–50 employees

Short description

ZAO VERTEX is a Saint Petersburg-based Russian pharmaceutical manufacturer founded in 1999, producing 430+ prescription drugs, OTC medicines, cosmetics, and supplements distributed through 83,000+ pharmacies and exported to 10 countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro industry

PRIMARYHLAIAJAC

OTC & Consumer Health Distributors

Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

SECONDARYHLAIAJAB

Specialty Pharmaceutical Distributors

Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

SECONDARYCRAFAEAK

Health & Pharmacy Omnichannel

Consumer Products & Retail/E-commerce & Marketplaces/Omnichannel Retail E-commerce

Keywords

• Pharmaceutical manufacturing
• Generic medicines production
• OTC dermatology products
• Prescription combination drugs
• Cosmetic and supplement brands

Headquarters

HQ city

Saint Petersburg

HQ country

Russia

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical products sales: Sale of prescription and OTC medicines, cosmetics and biologically active supplements through pharmacies, e-commerce platforms and direct sales
2. Export of pharmaceutical products: Export of pharmaceutical products and cosmetics to countries including Belarus, Kazakhstan, Uzbekistan, Armenia, Kyrgyzstan, Tajikistan, Turkmenistan, Azerbaijan, Laos

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

ZAO VERTEX is a Russian pharmaceutical manufacturer that develops, produces, and distributes prescription medicines, OTC drugs, cosmetics, and biologically active supplements. The company operates a 56,500+ m2 GMP-certified Innovation and Production Complex and offers 430+ product positions including original combination drugs without analogues in gynecology, dermatology, otorhinolaryngology, cardiology, and flu/cold treatment. Products are sold under sub-brands such as ALERANA, ASEPTA, GINOKOMFORT, LA-KRY, LE SANTI, NORMAVEN, and CAMELOX through 83,000+ pharmacies, 50+ e-commerce platforms, and export channels in 10 countries.

Product overview

ZAO VERTEX (ВЕРТЕКС) is a Russian pharmaceutical company manufacturing affordable medicines and innovative products. The company operates as a unified portfolio of prescription drugs, OTC medicines, and cosmetic brands. Core prescription products include original combined drugs like ТЕТРАДЕРМ® and ЭЛЬЖИНА® for dermatology and gynecology. The cosmetic portfolio is organized around sub-brands: ALERANA® (hair care with minoxidil-based treatments), ASEPTA® (oral care), GINOKOMFORT® (women's health), LA-KRY® (sensitive skin care), LE SANTI® (microbiome care), NORMAVEN® (vein care), and CAMELOX® (cosmetic products). The company produces over 430 product positions across drugs, cosmetics, and biologically active supplements distributed through 83,000+ pharmacies in Russia and 10 countries.

Differentiator

Problem solved

Functional benefit

Brands

• ALERANA: Hair care products including shampoos, balms, masks, sprays, and vitamin complexes for hair growth stimulation and against hair loss.
• ASEPTA
• GINOKOMFORT
• LA-KRY
• LE SANTI
• NORMAVEN
• ФРИНОЗОЛ (Frinozol)
• ТЕТРАДЕРМ (Tetraderm)

Products and services

• ALERANA® Consumer cosmetic brand of hair care products for hair growth stimulation and against hair loss, including minoxidil-based sprays, shampoos, balms, masks, vitamin-mineral complexes, and eyelash/eyebrow stimulators, sold through pharmacies and e-commerce.
• ASEPTA® Consumer oral care brand offering mouth rinses and related products for sensitive teeth and gum care, distributed through pharmacies and e-commerce.
• GINOKOMFORT® Consumer women's health brand offering intimate care products for gynecological use, sold through pharmacies and e-commerce.
• LA-KRY® Consumer skincare brand providing anti-inflammatory non-hormonal products based on natural components for sensitive skin, including creams, cleansing gels, diaper cream, emulsions, and acne care lines for children and adults.
• LE SANTI® Consumer skincare brand with a biotic complex for normalizing skin microbiome and restoring natural protective mechanisms, providing basic care for dry and atopic skin.
• NORMAVEN® Consumer vein toning brand providing anti-edematous leg care products, including foot cream and toning spray to relieve leg fatigue and heaviness.
• CAMELOX® Cosmetic brand included in VERTEX's product portfolio, distributed through pharmacies and e-commerce channels.
• ТЕТРАДЕРМ® (Tetraderm) Original prescription dermatological cream combining four active substances — mometasone, econazole, gentamicin, and dexpanthenol — to treat inflammatory skin conditions with antibacterial, antifungal, anti-inflammatory, and regenerative effects. No analogues in Russian market.
• ЭЛЬЖИНА® (Elzhina) Original prescription gynecological vaginal tablets combining ornidazole, neomycin, prednisolone, and econazole, providing antibacterial, antifungal, and anti-inflammatory effects for treating bacterial vaginitis and vulvovaginitis caused by Candida.
• ФРИНОЗОЛ® (Frinozol) Original prescription combined nasal spray containing phenylephrine and cetirizine — the only registered drug with this combination in the State Register of Medicines — for treatment of nasal and paranasal sinus diseases.
• ФРИЗАНТА® (Frizanta) Prescription antibacterial nasal spray for treating diseases of the nose and paranasal sinuses, launched December 2024.
• ALERANA® PHARMA CARE Targeted-action hair care product line under the ALERANA brand, including specialized shampoos (extreme nourishment, keratin restoration, maximum volume, freshness for men, ultra detox, protection against hair loss) and balms for stimulating growth, intensive nutrition, and hair health restoration.

Quantifiable outcome

• Up to 30% annual growth in production volume
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered minor and core.

• Dr. Reddy'sminorOthers · 4 August 2026Deal for transfer of rights to gynecological drugs portfolio.
• Almazov National Medical Research CentrecoreStrategic or Co-development Partner · 1 January 2019Contract on scientific cooperation for development of cardiac drugs that have no analogues in the Russian market.
• Almazov National Medical Research CentrecoreStrategic or Co-development Partner · 1 May 2016Agreement on scientific collaboration for development and performance of pre-clinical, clinical, pharmaceutical and economic research of medicinal products.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Market position

Strengths5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCFNjjK9p8ZuE43NDUH-Mfwg
• LinkedInlinkedin.com/company/zao-vertex

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ZAO VERTEX